Health IQ

Commercial

CPRD38

Sickle cell disease (SCD) is a condition that represents a significant unmet medical need. It is one of the most prevalent genetic disorders causing substantial illness and death and is responsible for a high number of hospitalisations annually. SCD patients suffer unpredictable and recurrent complications due to blocked blood flow to organs. This blocked blood flow, combined with haemolytic anaemia, can lead to multi-organ damage and early death.

With current advancements in drug research, there is hope that Sickle cell disease (SCD) can be managed by a once daily oral direct-acting haemoglobin modifier for chronic, prophylactic treatment of patients which would in turn reduce the morbidity, mortality and health care costs associated with them. However, there is limited understanding of the most at-risk patients which would affect the impact of targeted treatments if they are to be made available on the NHS. There is also a limited availability of knowledge on the risk of adverse clinical outcomes such as stroke in this group.

11/05/2021

Release